SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature
Source : https://www.nmd-journal.com/article/S0960-8966(22)00650-2/fulltext
Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction (NMJ). MG has an incidence of 30 per million/year in adults but is rarer (1-5 per million/year) in children under the age of 18 years [1].
Relevance: Here we report 7 cases of new-onset myasthenia gravis in timely association with SARS-CoV-2 vaccination, including the first paediatric case identified to date. We also reviewed the literature for other new-onset MG cases reported within 4 weeks of SARS-CoV-2 vaccination and discuss our findings in the context of altered (auto)immunity following SARS-CoV-2 vaccination and/or infection.